PEAK6
ABCL icon

PEAK6’s AbCellera Biologics ABCL Stock Holding History

PEAK6’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$179K Sell
51,200
-74,500
-59% -$268K ﹤0.01% 2303
2025
Q4 		$430K Buy
125,700
+58,400
+87% +$261K ﹤0.01% 2156
2025
Q3 		$339K Buy
+67,300
New +$297K ﹤0.01% 2289
2025
Q2 		– Sell
-1,100
Closed -$2.45K – 2909
2025
Q1 		$2.45K Buy
+1,100
New +$3.15K ﹤0.01% 2838

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PEAK6's ABCL Position: Q3 2025 in Review

PEAK6 sold out of AbCellera Biologics (ABCL) in Q3 2025, closing a stake of 136,614 shares — an estimated $602K sold.

PEAK6 first reported a position in ABCL in Q4 2024 and held it in 3 quarters. The position peaked at $586K in Q4 2024. 141 funds tracked by Wall St. Rank hold ABCL as of Q3 2025.

  • PEAK6 reported no remaining AbCellera Biologics position as of Q3 2025 after selling out during the quarter.
  • PEAK6 sold 136,614 AbCellera Biologics shares in Q3 2025, an estimated $602K.
  • PEAK6 first reported a position in AbCellera Biologics in Q4 2024 and held it in 3 quarters.
  • PEAK6's AbCellera Biologics position peaked at $586K in Q4 2024.
  • 141 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2025.

Based on PEAK6's 13F filing for Q3 2025, filed 14 Nov 2025.